Personalized Coronavirus Treatment Systems and Novel Inhibitors

A next-generation approach to combating coronavirus infections, leveraging machine learning, genomics, and advanced compound generation to provide personalized treatment regimens and novel inhibitors.

The original patent disclosed compounds and compositions for treating coronavirus-associated diseases. However, these approaches were limited by their 'one-size-fits-all' nature, neglecting individual genetic variations and the rapidly evolving coronavirus genome. The new inventive concept addresses these limitations by integrating machine learning, genomics, and advanced compound generation to provide tailored treatment solutions.

The new inventive concept comprises a system for personalized coronavirus treatment, utilizing a database of genomic data and a machine learning model to predict optimal treatment regimens based on individual genetic profiles. Additionally, a deep learning-based generative model is used to identify novel coronavirus inhibitors with predicted antiviral activity. These inhibitors are then screened against coronavirus proteases to identify those with inhibitory activity. The system also includes a dispenser for administering the predicted treatment regimens to subjects. Furthermore, the inventive concept encompasses compositions for treating coronavirus infection, comprising nanoparticles encapsulating different antiviral compounds selected based on their predicted synergistic effects against coronavirus proteases.

The new claims introduce a paradigm shift in coronavirus treatment by integrating machine learning, genomics, and advanced compound generation. The use of machine learning models to predict optimal treatment regimens and the generation of novel inhibitors using deep learning-based generative models are novel and non-obvious features that distinguish the new inventive concept from the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, such as neural networks or decision trees, or the integration of additional data sources, such as electronic health records or wearable device data. Variations of the generative model could include the use of different training datasets or the incorporation of additional molecular descriptors.

The new inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the context of personalized medicine and targeted therapies. The ability to provide tailored treatment solutions and novel inhibitors could revolutionize the treatment of coronavirus infections, offering a competitive advantage in the market.